Nurix CSO logs RSU vesting and tax share sales
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported RSU vesting and related tax-share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported RSU vesting and related tax-share sales. On January 30, 2026, RSUs covering 3,207, 2,000, 3,750, and 2,859 shares were converted into common stock at $0 per share.
To cover tax withholding from these RSU vestings, Hansen sold 4,797 and 98 common shares in mandated “sell to cover” transactions at weighted average prices of $16.5826 and $17.3717. After these trades, Hansen directly beneficially owned 83,672 common shares and held 25,725 RSUs.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
Hansen Gwenn
Role
Chief Scientific Officer
Sold
4,895 shs ($81K)
Approx. gross sale proceeds
$81K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,207 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 2,000 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 3,750 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 2,859 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,207 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,859 | $0.00 | $0.00 |
| Sale | Common Stock | 4,797 | $16.5826 | $80K |
| Sale | Common Stock | 98 | $17.3717 | $2K |
Holdings After Transaction:
Restricted Stock Units — 46,475 contracts (Direct);
Common Stock — 83,672 shares (Direct)
Footnotes (9)
- F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3. Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F4. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F5. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- F6. RSUs do not expire; they either vest or are canceled prior to the vest date.
- F7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F8. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F9. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Nurix (NRIX) report for Gwenn Hansen on January 30, 2026?
Nurix reported RSU vesting and related tax sales for its Chief Scientific Officer. On January 30, 2026, multiple RSU awards vested and converted into common stock, followed by mandated “sell to cover” transactions to satisfy tax withholding obligations under the company’s equity incentive plans.
How many Nurix (NRIX) RSUs vested and were converted into common stock for the CSO?
Four RSU tranches vested and were converted into common stock. On January 30, 2026, awards covering 3,207, 2,000, 3,750, and 2,859 RSUs converted into an equal number of Nurix common shares at an exercise price of $0 per share, reflecting standard RSU settlement mechanics.
How many Nurix (NRIX) RSUs does the CSO continue to hold after the reported vesting?
The filing shows continuing ownership of several RSU awards. After the January 30, 2026 conversions, remaining RSUs reported include 2,000, 18,750, and 25,725 units, each representing a contingent right to receive one Nurix common share upon future vesting, subject to continued service conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
